RxSight, Inc. (RXST) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Thanks, operator. Joining me today are RxI's President and Chief Executive Officer, Aziz Motivala, along with Chief Financial Officer Mark Wolterding. RxI put out its financial results earlier today for the 3 months that ended June 30th, 2026. You can find a copy of that press release right now on the company's website. Before we get started, I want to remind everyone that what we say and how we answer questions on this call represent management's views as of today, and those remarks will contain forward-looking and opinion statements — things like predictions, estimates, plans, and expectations. Actual results could differ materially from what's expressed or applied because of certain risks and uncertainties. Details about these dangers and unknowns can be found in fuller form within the press release we put out today, as well as in the documents we file with the Security and Exchange Commission, or SEC. You can access our SEC filings either through our website or via the SEC's own site. One word of caution for investors: avoid putting excessive weight on these statements, and we refuse any responsibility to update or alter these forward-looking statements unless the law demands it. We will also discuss some non-GAAP financial measures. Information regarding non-GAAP financial measures, which includes reconciliations to the closest comparable GAAP measures, is provided in the press release. Also, be aware that a recording of this conference call will be made available on our Investor Relations website. Thanks, Oliver. Good afternoon, everybody, and thanks for being here. It's a real pleasure to be at our site and to have this chance to talk with all of you today. Eye care has been the focus of the bulk of my professional life, and it's a field of health care where there's a major chance to transform patients' quality of life in meaningful ways. It's an enormous privilege to become part of a business whose mission centers on enhancing how people see — that's a big part of what drew me to ArcSight. Now I'll pass things over to Adi. In my latest role as Chief Commercial Officer at Tarsus Pharmaceuticals, I was involved in establishing and guiding the commercial approach for a product that stands out as one of the most significant category creators in eye care. Going through that taught me how vital it is to have innovation that sets you apart, to execute with discipline, and to engage customers effectively. I'm eager to apply what I've learned as we focus on improving how we execute and on generating value for physicians, patients, employees, and shareholders. I want to express my gratitude to the board of directors for trusting me with this opportunity, and I also want to recognize the whole RxSight team. During these last two weeks, I've felt incredibly welcomed by everyone, and I've been struck by the innovative spirit, the dedication, and the problem-solving attitude that exists throughout the company. Considering everything this group has achieved, I wasn't taken aback, yet it has deepened my enthusiasm for what lies ahead. I'd also like to pause and acknowledge Ron Kurtz, whose leadership was instrumental in developing the ARC site and in making the world's sole adjustable IOL platform available on the commercial market. It makes me happy that Ron will continue serving as chief medical officer — his clinical expertise, deep familiarity with the products, and relationships with physicians will remain highly valuable, and I look forward to working closely alongside him as we advance the platform. The RxSight team has developed a truly differentiated technology, one that carved out an entirely new category in cataract surgery. Being able to fine-tune and tailor someone's eyesight after the procedure is genuinely one of a kind, and it tackles a central objective of cataract care — assisting patients in reaching the vision they want. In the process, he has built up a strong foundation of committed doctors and practices who have deep faith in our technology and have seen for themselves the difference it makes for patients. Since I've only been at ArcSight a brief time, I'd like to share a few early thoughts and observations. During the past several weeks, I've devoted a lot of time to listening, learning, and sitting down with leaders throughout the organization, plus important customers in the ophthalmic community. To drive change, I first need a deep grasp of the business, to pinpoint the core difficulties, and to figure out where our impact can be greatest. That said, what I've heard so far in these early conversations has confirmed that adjustability's value is still very compelling, and that doctors acknowledge how differentiated the technology is and how it can give their patients vision that's more precise and personalized. I've also found that the majority of surgeons pick LAL for the patients who matter most to them — even relatives of their own; for instance, at a dinner recently here in Orange County, one ophthalmologist told me she'd selected LAL for her brother as well as her sister. I also spoke not long ago with a different ophthalmologist in Florida who placed LAL in both of his B, and those choices show the tremendous confidence that the ophthalmic community has in our technology. Backing up this physician confidence is a large body of clinical and real-world evidence showing how precise, consistent, and versatile our technology is. A recent illustration is a phase four registry that appeared in the Journal of Cataract and Refractive Surgery. Over 1,100 patients at 126 sites took part in that study, which reported solid refractive and visual results among patients with and without previous corneal refractive surgery. Findings like these — their breadth and consistency — strengthen RxSight's clinical proposition and the value adjustability brings to physicians and patients. On top of that, the collaboration with Alcon we announced recently marks a major milestone for the company. It gives further outside validation of the technology and what it could achieve more broadly. It also brings meaningful non-dilutive capital via the $200 million in upfront and potential future milestone payments, together with the prospect of substantial long-term royalties. Above all, this collaboration bolsters our conviction that adjustability represents the future of cataract surgery. Even so, there's a great deal of work in front of us to turn this opportunity into wider adoption. As I keep working through my evaluation, I want to make sure we retain the room to scrutinize the business fully and to take the steps we judge to be best for the company's and our shareholders' long-term interests. Although the trends underneath are still broadly in line with the outlook we gave before, this effort is going to take time, and our earlier outlook shouldn't box us in when it comes to actions we might eventually conclude are the right ones. So we've chosen to pull the full-year financial guidance we had previously issued. We know that guidance came out not long ago, and this was not an easy call for us to make. We believe this is the correct step to take at a time when our evaluation is still ongoing. We'll resume formal guidance in early 2027. Instead of jumping right into what my initial priorities are and how I see things moving forward from here, I'm going to turn it over to Mark, who will take you through the financial results for our second quarter and offer some directional thoughts regarding the remainder of the year. Mark? Thanks, and thank you, Aziz, and good afternoon to all of you. Consistent with the revenue range we shared in our preannouncement last month, total revenue for the company in the second quarter was $33.7 million, including $6.5 million that we recognized related to our strategic collaboration agreement with Alcon. That figure reflects the share of the initial milestone payment tied to our licensed intellectual property. Leaving out revenue related to Elkhorn, product sales in the second quarter reached $27.2 million, a decline of 19% versus the same period a year earlier, driven by intensified competitive trialing along with broader headwinds in the marketplace.
During Q2, LAL unit volumes totaled 24,917, down 9% versus the prior-year period. Revenue from LAL procedures hit $24.5 million in Q2, representing 90% of RxSight product revenue. We placed 12 LDD units in the quarter, which added $1.3 million in quarterly revenue, and ended the quarter with 1,166 LDD units in the installed base. Excluding the partnership benefit, Q2 gross margin was 71.2%, compared with 74.9% a year earlier. That decline versus last year was primarily driven by increased inventory-related costs resulting from slower-than-expected inventory flow-through, including the favorable contribution of collaboration revenue. Gross margin for Q2 came in at 76.7%. Second quarter 2026 SG&A expense totaled $30.4 million, a 5% increase over the prior year period, largely driven by legal and consulting expenses tied to the collaboration. Research and development expenses for the second quarter were $9.2 million, compared with $10.2 million in the prior year period. This year-over-year decrease was mainly the result of lower personnel-related expenses. We posted a net loss of $12.1 million in the second quarter, equal to 29 cents per basic and diluted share, on 41.5 million weighted average shares outstanding. Stock-based compensation came to 7.5 million dollars, producing an adjusted net loss of 4.6 million dollars, or 11 cents per share. At the end of Q2, our cash, cash equivalents, and short-term investments stood at about $209 million. That amount does not include the $60 million upfront payment connected to the partnership agreement, which came in after the quarter closed. As Aziz mentioned previously, while the trends we're currently seeing in the business are largely consistent with our earlier expectations, we've decided to pull our formal financial guidance for full-year 2026 while we complete our assessment of the business. With that said, we want to share some directional thoughts on the main factors we believe will influence how we perform for the remainder of the year. We continue to anticipate recognizing $30 to $40 million in revenue related to the Alcon Strategic Agreement. We’ll record revenue only when specific performance obligations are met, which means the quarterly timing won’t be steady. Given what we currently expect, Q3 should bring only a small amount of revenue, while the remaining portion of the $30 to $40 million would be recognized in Q4. As for the core business, the trends so far this quarter are encouraging, especially the confidence physicians keep showing in our technology. Even so, we anticipate that competitive pressure will persist, product trialing will continue, and the usual Q3 seasonality, along with broader marketability, will shape how we perform for the rest of the year. As Aziz mentioned earlier, we’ll start giving formal financial guidance again when we release our fourth quarter 2026 results in early 2027. Okay, I'll hand things over to Aziz now. Thanks, Mark. The results we posted for the second quarter make clear there's still plenty of work in front of us. Of course — launches from competitors, the broader market environment, seasonal patterns, and whether patients can afford treatment all genuinely matter, and any single one of those factors can shift how a given quarter turns out. That said, based on everything I've seen so far, I believe there's substantial room to sharpen both our strategy and the way we carry it out. We've built up a considerable installed base, and the people we serve have real conviction about the potential of this technology. Even so, the procedure volume and utilization we're getting today fall short of what this platform ought to be capable of achieving. We have to make sure our commercial strategy, our customer support model, and our capabilities are right so practices can fold the light adjustable lens more completely into their workflows and make adjustability a bigger and bigger piece of what they offer in cataract surgery. My near-term priorities are simple. One, we'll finish a rigorous review of the business and our commercial model. Two, we'll strengthen the commercial team and drive higher utilization across the install base. As part of that growth plan, we've approved a roadmap to eventually double our US sales team, which lets us widen our reach while still supporting the customers we already have; funding for this expansion should come mainly from shifting resources inside the company, and it shouldn't raise total operating expenses in any material way. Three, we'll raise the bar on execution and operating discipline. That means better forecasting, supported by clearer insight into the fundamental drivers of the business, plus more agility so we can respond fast when the marketplace shifts. Finally, we'll continue advancing our in-house development lineup for the upcoming generation of adjustable lenses, as these are designed to enhance workflow efficiency, boost performance, and expand the number of patients who could gain from adjustability; additionally, we'll establish the necessary procedures and resources to propel our partnership with Alcon forward, which represents significant strategic endorsement for our platform. We'll concentrate on achieving development goals and driving these upcoming products closer to market launch. That partnership ought to generate considerable value over the long term via forthcoming royalties and bring the advantages of adjustability to the greatest possible number of cataract patients; this effort will take time to materialize. Finishing the assessment comes first; after that we have to turn those insights into action, carry them out consistently throughout the organization, and in the end shape how physicians and practices behave; we'll make disciplined choices, set clear priorities, and show measurable progress. As this effort moves forward, we'll give you more clarity on our strategic priorities, the steps we're taking, and the milestones we'll use to gauge progress. We'll also be candid about what's working, what needs more focus, and how our thinking is changing. We expect to offer more detail in our next quarterly update. When I joined our site, I knew there would be a lot of work in front of us. The reason I joined this company is that what we're building has real importance. There's a big opening in the marketplace, and I believe we can convert that promise into substantial outcomes for patients, for customers, and for shareholders — which encompasses the $0.11 and $0.29 numbers connected to the metrics I mentioned.
Oh, excellent. Aziz, welcome aboard, and congratulations on taking on the new position. You've already spoken about this somewhat, but I have two things for you. To start, could you describe your role and share a bit about what prompted you to join? What was it regarding our excitement, the company, the product, and the opportunity that convinced you to come here? Then I've got a follow-up.
Of course, I appreciate that. RxSight is genuinely a one-of-a-kind organization. I've worked within eye care for a long while. One thing I hear repeatedly is that this ranks among the most significant advances in cataract surgery technology. I've spoken with numerous thought leaders and key opinion leaders, and you get this same message over and over. That was quite compelling. Once I explored the business more deeply and, clearly, took on this position, it truly strengthened my conviction that this represents what cataract surgery will look like going forward. Another factor I considered is that there's considerable overlap with what I've been doing lately. I invested a great deal of effort creating a brand-new category within eye care, and in my view this remains an emerging category in eye care. It's a space where we're establishing the worth of adjustability, the capacity to customize outcomes for patients, and genuinely reshaping cataract surgery. When you consider it, many elements line up. We're altering how physicians behave. We must modify practice workflow; yet the technology we're working with produces excellent results; so there's substantial overlap between the situation at RxSight and my prior experience; and it's a field where, since I'm in eye care, I hear my physician peers speaking with real enthusiasm.
And that's what makes me enthusiastic about the future potential here too. I realize it's extremely early still. We're only days into this position. Do you have any initial thoughts on what you believe caused the slowdown in growth and the reduced utilization, along with any early ideas about how you could tackle this and, you know, get the business growing again following a deceleration? Thanks very much.
No, that's the correct thing to ask. And clearly, we're currently conducting a comprehensive business assessment to determine the proper strategy and direction that will steer the company toward truly maximizing what we believe the long-term value here is; and perhaps I'll begin with a few items I'm picking up from physician peers. I'm devoting considerable time to conversations with doctors so I can genuinely grasp the dynamics. What I can share is that doctors keep believing this is among the finest technologies. Not a single person I've spoken with has told me they've maxed out their capacity to perform LALs. Every one of them has said they could handle more. The key thing here is that we need to put the correct plan in place. And I think what took place — my belief is that when you enter a market such as this one, you build that first group of users, and frankly, at this point we're shifting toward generating depth, correct? We've already built a wide user base, and making that shift toward depth requires some time and a somewhat different approach. So I believe what you'll get from us is an evaluation that lays out which levers exist, which strategies are available to us, and how we can carry them out to genuinely generate that deeper level of utilization. So the brief response to what you asked is this move from breadth toward depth, and what gives me real encouragement about what's achievable here is what physicians keep telling us — they continue to feel this is the finest technology, and not one doctor I've spoken with has told me they've reached the limit of what LALs can do for them. It simply comes down to us collaborating with those practices to enhance workflow, assist in finding the appropriate patients, and truly join forces to spread education about the outcomes this technology produces, which it does with great consistency. Many thanks.
Hi, Jacqueline here, filling in for Ryan. I appreciate you taking our questions. So, LDD placements reached 12 units during Q2. Given that your first LDD rental unit has now been placed, going forward, what portion of your LDD pipeline do you expect to move toward rental units rather than capital purchases, especially as you pursue international markets to reduce the barrier to entry?. Mark Benthien Hi, Jocelyn, this is Mark. I appreciate the question. Yes, we were pleased with our initial rental contract during the second quarter, and it's an area we'd be willing to expand, particularly as, just as you mentioned, we aim to grow further into international markets. I can't give you a specific figure or tell you what level we're aiming for exactly. What I think we want to accomplish is providing a variety of solutions and opportunities to customers, truly letting them work alongside us and choose whichever path makes the greatest sense and benefits both sides. So it's an area we'll keep pursuing. I don't have a method to, as I mentioned, attach a precise number to it, but the potential of these deals excites us. Thanks. And additionally, with the recent regulatory clearances in markets such as New Zealand and continuing commercial work across Europe and Asia, has the Alcon collaboration changed your independent OUS commercial approach in any way?. No, I think the way I view that is on a broad scale, correct — when we survey the globe, The importance of cataract surgery remains elevated. Adjustability remains a technology that thought leaders and surgeons worldwide keep telling us they have strong interest in. So we view that as an opportunity that keeps going. I believe we must be quite deliberate when entering markets that hold genuine promise, where customers can be reached, and where we can gain meaningful traction. That's why our approach to expansion is careful and systematic. This is a distinct and separate strategy from what we're doing with Alcon, where the goal is broadening the availability of adjustability over a larger selection of lenses. Naturally, that translates into serving a wider group of patients. To my way of thinking, there's a future in which all premium lenses carry the benefit of adjustability, and that would be extraordinary; so I see these as linked yet somewhat separate when it comes to how we pursue them strategically.
Good afternoon. Thanks for taking the question. Welcome and congratulations, Aziz. Could you tell us about what you accomplished earlier in your career, or what made those previous eye-care organizations work well, that could carry over to RxSight? Thanks for asking, and I appreciate the nice comments. A handful of factors strike me as genuinely useful in our situation.
When it comes to the way we run things, I believe there are a few key elements. Operating discipline is one — Mark has begun putting that in place during his time here, and we keep honing it. Another is staying truly near the customer, building that sense of connection. That's something we took great pride in across several fields where I've built my career, including eye care. Relationships with eye care physicians are usually quite collegial and highly collaborative. As I said before, they're enthusiastic about this technology and eager to discover methods to broaden its use, and it falls on us to direct that excitement. So that's two: operational discipline and customer connection. The third is a genuinely deliberate approach to ongoing education and to spreading the data and real-world outcomes this technology delivers. Wherever I've helped grow a market throughout my career, educating the community thoughtfully has always been an essential cornerstone. I believe there's far more we can accomplish here to champion the benefits of adjustability. Physicians possess case studies — real-world ones plus those from the clinic — so I see chances to grow and dig deeper into the worth of education. So how we function, staying very close to customers, and truly capitalizing on the surround-sound education and experience physicians bring are a few examples. There are likely additional ones, but clearly we're evaluating where else we might capitalize on things and act in this business's best interest, since plenty of elements can translate, yet this is likewise a distinctive opening. So we aim to be deliberate about customizing our strategy to whatever will maximize value for LAO. That's useful. And just one more about the Alcon collaboration. Actually it isn't regarding Alcon itself, but that Alcon deal wasn't exclusive. Could you picture striking comparable arrangements with other firms? Thank you for the question. I believe we've been quite deliberate. The management team collaborates with Alcon. Alcon leads this industry. Their capabilities are excellent. And of course, we contribute a great deal here regarding adjustability. So our present focus is on making this partnership truly bear fruit, achieving the milestones, which matter greatly to us given the cash they can bring in over the coming years, followed by the royalty. So it isn't exclusive, yet as things stand today I prefer concentrating on what lies directly ahead, which is a genuinely valuable chance with an excellent partner to broaden use of this technology to a wide patient base and across numerous IOL platforms. So it isn't exclusive, which clearly leaves us options over the long run, but if you ask where our focus sits today, it's on maximizing the worth of our relationship with.
Hi, thanks for taking the question. One question is for Aziz, and congratulations again on stepping into the new position. You described a few of the areas you'll be concentrating on, and those seemed to line up with initiatives we've been discussing for several quarters now, things like better utilization and growing the sales team. So perhaps you could share your vision or plan for the company, along with what overlaps and what doesn't. And I suppose I'll put my second question out there right away. How are you approaching this given that the guide was withdrawn so we can stay flexible, and does that point toward larger changes coming down the road? Thank you. Sure, maybe we start with the guide, right? I believe you heard Mark mention during the prepared remarks that the business overall is performing slightly better than it did in previous quarters. As we enter the third quarter, some improved trends are showing up. That's terrific, and basically it tells me we're taking some correct steps. That said, I want to ensure we can carry out a careful evaluation. Should decisions be necessary, we're able to make them very fast here and get the business back on course, not only to finish the year strong, but truly to position the business for the coming years of growth. That connects to your following question: what stays the same, what changes? Basically, what you're picking up on is a strategy, correct? We're engaging deeply with accounts. We're moving nearer to the customer. We're going to have a wider sales organization to be in front of the customer frequently. Those are basics. I believe there's far more to uncover here to genuinely lift this organization and unlock LAL's full potential. That sort of returns to the reason I chose to join. I truly think this has enormous potential and that we've only begun to tap it. It's really about setting up a larger, overarching strategy. I think certain things we're doing are squarely on the right path. I think there's additional work we can take on. And I think you nailed it — this isn't about sending any signal regarding how the business is doing today relative to the earlier guidance. It's really us saying, look, we might need to make further changes, and we simply want to allow for any disruption to the business that could occur during that intense period. But the hope is that we accomplish that within an intense period, get the business back on track, bring it to a long-term growth trajectory, and then provide all of you with a solid visibility line regarding where we're going in 2027.
All right, great. Thanks for taking the questions. Welcome, Aziz. Looking forward to working with you and congrats on the new role. So I suppose the opening thing I'd ask, Joe, relates to how you're sizing things up, because I realize we'll get additional detail when the following earnings call happens. By that point, most of it should be wrapped up. And then, if possible, could you speak broadly about which KPIs you pay attention to, plus how you handle guidance? Absolutely. Right, so clearly we aim to be careful regarding the way we carried out the assessment, yet we also intend to be quite deliberate about completing it fast and with real discipline, allowing us to put that behind us and shift toward positioning the company for growth. On a precise schedule, my expectation is that next quarter brings fresh information. A helpful frame here is that our commitment is to provide 27 guidance. at the point we report year-end earnings. That moment works well for saying, look, these are every adjustment we've implemented, this is how we're aligning the company around the 27 targets, and that will probably carry some consequences for the way we view the business going forward too.
So I'd say that's roughly the timing, the schedule, and the structure we have in mind. When it comes to KPIs, the most evident metric is how many LALs we're able to place into patients' eyes — that clearly comes first and above all else. As for additional measures, an element of the evaluation involves asking whether there are other KPIs genuinely tied to the direction the business is taking. That too forms part of the evaluation and will form part of the plan. You can picture it like this: here's our strategy, here's the way we'll carry it out, here's the way we'll track it, and here's what you should expect to see. That's essentially the formula we intend to present externally over the next several months, and definitely once we're positioned to issue guidance once more for 27. Yeah, that's quite useful. And then, you've already sat down with a number of those specific customers, and it sounds like feedback has been largely positive, both on opportunities and on what's possible there. Perhaps looking at the other side, though — what problems, points of friction, or difficulties did they bring up with you? Certainly. I'd say this is somewhere things have been truly striking, since we keep receiving plenty of encouraging input, and even when it comes to difficulties voiced by physician colleagues — a few of whom I've personally known for a great many years — practically every one of them tackles it with a mindset focused on solutions, correct? Hey, I'd like to implant more LALs. I'm merely attempting to work out how to make workflow as efficient as possible, for example. Hey, I'd be thrilled to use a greater number. Let's determine which patients are the ideal ones. Where should a multifocal go? Where should this go, and what's the way to grow my usage or widen what I offer patients? So those are the sorts of things reaching our ears. Which patient is ideal? What's the way to fold it into a workflow? Those can genuinely be resolved without much trouble as time passes. This concerns education, and this concerns circulating best practices among clinics. And in those areas, I believe you'll witness considerably greater depth from us when it comes to a wider strategy. Yet for me, it's genuinely quite heartening, correct? There isn't a substantial, major barrier standing in the way of unlocking this. It'll require a while to ensure we nail those messages, nail the positioning, secure physicians' buy-in, and truly grasp what will represent — connect with them, though I think that's precisely where, as we brought up earlier in one of the previous questions, the worth of education lies: teaching them that this is the way to get the most out of it in your practice. This is the way to select the appropriate patients. I mean, I spoke with a single doctor who had completed his 3,000th eye. Some people have really mastered this area, and my view is that if we could learn from their expertise and deploy it broadly, a lot of the obstacles that folks imagine would come down. Okay, excellent. Appreciate it.
Stephen from Stifel, we're ready for you. Hey everyone, thanks for fielding our questions, and Aziz, congratulations on the new position. Aziz, I've got just one thing to ask. As we consider the pharma background you bring, it would be helpful if you could share your perspective on the anterior segment space in general, whether seen through a physician's eyes or from how a practice operates. I'd really like to get your perspective on what you might call the overlap of pharmaceuticals and hardware within cataract and refractive procedures, and for those anterior segment surgeons, which segments are seeing growing attention at the practice level — where would you say the puck is moving as we consider the customer? Thanks. That's a great question, and it's a topic close to my heart, given how many years I've devoted to this field and how intentionally I've thought about the places where I can contribute something meaningful — essentially, where the puck is going, right? That's both the science and the craft involved here. The biggest shift I'm seeing across the board—and this connects to what I dealt with before, and I think it's really relevant at ArcSight—is that patients' expectations keep climbing. They're looking for real outcomes from their doctor. Just being okay isn't enough these days, if that makes sense. Right? Everyone wants flawless eyesight. They don't want anything getting in the way. Consider who's having cataract surgery now compared with, let's say, 15 years back. It's a completely different group. Folks are leading far more active lives. Once they're past their cataract years, they still want to do all the things they could do when they were younger. I believe physicians are trying to find ways to get the most value for their patients. Expectations around satisfaction keep going up, and doctors want to fulfill that need — they sincerely aim to produce excellent results. Because of this, I'd say there's a greater willingness to pay more for technologies and products, in pharma as well as devices, that deliver genuinely meaningful outcomes. Take therapeutics: a small therapeutic advantage won't be enough, unless the disease is one that seriously threatens sight — what they want are products that truly change things. I'd say the same holds true in the surgical area. Just being somewhat improved won't satisfy them. What they want to know is: is it possible for me to stop wearing glasses? Can the results truly be perfect? When I considered what's possible here, I realized this technology accomplishes that in the surgical setting. That ability exists, and I'm confident we can genuinely address the rising expectation among patients for continuously better outcomes and their demand for perfection, together with what our technology enables us to deliver in meeting that need. I believe that intersection is somewhere we can excel tremendously. That's wonderful. Thank you, Aziz. Congratulations again.
Thanks. We don't have any more questions right now, so that wraps up today's call. I appreciate everyone for being here. You can go ahead and hang up now. This live transcript was generated automatically, with no human involvement or checking.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete RxSight, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to RxSight, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.